Source: CTD Holdings, Inc. 9/27/19
CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology
company that develops cyclodextrin-based products for the treatment of
disease with unmet medical need, today announced a new collaboration
with the Chattanooga Center for Neurologic Research (CCNR) based in
Chattanooga, TN. CCNR is a biomedical research company led by globally
recognized vascular neurologist Thomas G. Devlin, MD, PhD. In close
partnership with Erlanger Health System and the University of Tennessee
College of Medicine, Dr. Devlin has spearheaded the launch of various
biotechnology companies whose commercialized products are having
widespread impact on neurologic disease.
The collaboration is expected to lead to selection of CCNR and the
Erlanger Health System as a site in CTD’s clinical trial in Alzheimer’s
Disease, now in the design stage. As a first step in the collaboration,
CCNR and CTD representatives will exchange confidential information on
priority scientific topics and clinical capacity.
CTD Chairman and CEO N. Scott Fine said, “Given the significant overlap
between stroke, dementia, and Alzheimer’s disease, we are delighted to
undertake this collaboration with Dr. Devlin and his team as we build
our respective Alzheimer’s programs. Dr. Devlin’s expertise as a
world-class clinical researcher in neurovascular disease and stroke is
directly applicable as we build out the CTD Alzheimer’s platform.”
Alzheimer’s Disease affects 5.7 million Americans. The disease takes an
enormous toll on affected individuals, families and communities as loss
of memory and ability to manage daily functions worsens. There are no
approved disease modifying treatments. Physicians prescribe treatments
for symptoms associated with the disease: these are not effective in all
individuals.
Dr. Devlin said, “Tennessee is part of what’s known as the 'stroke belt'
in the United States, with a stroke risk over 30% higher than other
areas. We have turned this huge medical liability for our patients into a
tremendous opportunity to partner with the best biomedical companies
worldwide to spearhead new treatments. With Tennessee having the second
highest death rate from Alzheimer’s disease of any state in the United
States, we are now totally committed to continuing to identify visionary
and innovative industry partners to align with as we launch our next
major research initiative – Alzheimer’s disease. CTD Holdings is the
perfect partner and I anticipate years of close and productive
collaboration in our quest to cure Alzheimer’s.”
CTD Chief Scientific Officer Sharon Hrynkow, PhD stated, “Our proprietary cyclodextrin product, Trappsol®
Cyclo™, which has an affinity for cholesterol, has shown encouraging
findings in a single late-onset Alzheimer’s patient who has used it
through an FDA-approved expanded access program for more than one year
(see ClinicalTrials.gov NCT03624842).
We are excited about the collaboration with Dr. Devlin and his CCNR
team as we work to develop new knowledge about our drug’s potential
benefit to Alzheimer’s patients.”
For more information on Dr. Devlin’s current work using artificial intelligence applications to improve stroke care, see HERE and HERE.
About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that
develops cyclodextrin-based products for the treatment of disease. The
company’s Trappsol® Cyclo™, an orphan drug designated product
in the United States and Europe, is in three ongoing formal clinical
trials for Niemann-Pick Disease Type C, a rare and fatal genetic
disease, (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com
No comments:
Post a Comment